Acorda Therapeutics to Present at J.P. Morgan H&Q Healthcare Conference.Business Editors SAN FRANCISCO--(BUSINESS WIRE)--Jan. 7, 2002 Acorda Therapeutics will be presenting at the J.P. Morgan H&Q Healthcare Conference in San Francisco on Monday, January 7, 2002 at 1:30 p.m. PST PST Paroxysmal supraventricular tachycardia, see there . Ron Cohen cohen or kohen (Hebrew: “priest”) Jewish priest descended from Zadok (a descendant of Aaron), priest at the First Temple of Jerusalem. The biblical priesthood was hereditary and male. , M.D., President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Acorda, will provide an overview of the company's achievements in 2001 and discuss corporate goals for 2002. In 2001 Acorda achieved several important milestones. The company closed a $40 million round of financing and successfully completed Phase 2 clinical studies of its lead product, Fampridine-SR, in chronic SCI (Scalable Coherent Interface) An IEEE standard for a high-speed bus that uses wire or fiber-optic cable. It can transfer data up to 1GBytes/sec. (hardware) SCI - 1. Scalable Coherent Interface. 2. UART. and in MS. Acorda also identified two lead product candidates for its preclinical remyelinating antibody program, and launched an initiative to in license late-stage CNS See Continuous net settlement. CNS See continuous net settlement (CNS). product opportunities. "At last year's meeting we presented our goals for 2001 and I am pleased to report that we achieved all of them," Dr. Cohen said. "We expect 2002 to be pivotal year for Acorda, as we advance development of Fampridine-SR, and move our human monoclonal antibody, M1, towards clinical trials." Acorda Therapeutics is a privately held biotechnology company developing therapies for individuals with spinal cord injury Spinal Cord Injury Definition Spinal cord injury is damage to the spinal cord that causes loss of sensation and motor control. Description Approximately 10,000 new spinal cord injuries (SCIs) occur each year in the United States. (SCI), multiple sclerosis (MS), and other central nervous systems disorders. The Company's lead product, Fampridine-SR has completed Phase 2 clinical trials for chronic spinal cord injury, and for multiple sclerosis. Fampridine-SR restores the ability of damaged nerves to conduct electrical impulses, and is the only drug in clinical trials for individuals with chronic, or long term, SCI. The Company's human monoclonal antibody, M1, has been shown to remyelinate the central nervous system in animal models, and is in preclinical development for MS. Acorda is also developing protein- and stem cell-based technologies to regenerate and repair the spinal cord and brain. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion